Research programme: RAF kinase inhibitors - ArQule

Drug Profile

Research programme: RAF kinase inhibitors - ArQule

Alternative Names: ARQ 218; ARQ 680; ARQ-350RP

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ArQule
  • Class Imidazoles; Oxazoles; Piperidines; Pyrazoles; Pyrimidines
  • Mechanism of Action Mitogen-activated protein kinase inhibitors; Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA
  • 31 May 2006 This programme is still in active development
  • 31 Aug 2005 Preclinical trials in Solid tumours in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top